Tonix Pharmaceuticals Holding is focused on the development of innovative prescription medicines for challenging disorders of the central nervous system. Tonix targets conditions characterized by significant unmet medical need, inadequate existing treatments and high patient and physician dissatisfaction. The company’s core technology improves sleep quality for patients suffering with chronic pain syndromes, which is thought to translate into a reduction of daytime pain and other symptoms. For more information, visit the company’s Web site at www.tonixpharma.com.

The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies. Each year the annual event provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. For more information on Biotechnology Industry Organization (BIO), visit www.bio.org.

Let us hear your thoughts below: